Anemia And Other Blood Disorder Drugs Market Expected To Reach $16.87 Billion By 2030 As Growth Accelerates At 6.5% CAGR
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Anemia And Other Blood Disorder Drugs Market Expected To Reach $16.87 Billion By 2030 At 6.5% CAGR
The market for anemia and other blood disorder medications has experienced robust expansion in recent times. Projections indicate a rise from $12.46 billion in 2025 to $13.14 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.5%. Historical growth was driven by several factors, including a significant occurrence of iron deficiency anemia, the widespread presence of chronic kidney disease, a heavy dependence on blood transfusions, the extended utilization of erythropoiesis-stimulating agents (ESAs), and the existence of well-established protocols for hematology treatment.
Over the coming years, the market for drugs treating anemia and other blood disorders is anticipated to experience robust expansion. Projections indicate it will reach a value of $16.88 billion by 2030, with a compound annual growth rate (CAGR) of 6.5%. Several factors are expected to drive this growth during the forecast period, including the increasing adoption of gene therapy, the growing proportion of elderly individuals, heightened awareness surrounding blood disorders, the proliferation of specialized hematology clinics, and enhanced diagnostic rates. Key developments shaping this period comprise the growing incidence of chronic blood conditions, an uptick in the application of injectable treatments, the advancement of gene-based solutions for rare anemias, a heightened emphasis on personalized hematology approaches, and better accessibility to fundamental medications for blood disorders.
Download A Free Sample Report For Comprehensive Market Insights:
Anemia And Other Blood Disorder Drugs Market Growth Drivers And Industry Catalysts
The growing need for tailored medical treatments is anticipated to drive expansion in the market for drugs addressing anemia and other blood-related conditions. This approach, known as personalized medicine, relies on an individual’s genetic information to inform decisions about prevention, diagnosis, and therapy. Its increasing popularity stems from its capacity to provide more precise and effective treatments, ultimately enhancing patient results and long-term wellness. In the field of blood disorders, this market facilitates customized care by designing treatment strategies that target the distinct genetic or molecular features of each condition. For example, data from the American Psychiatric Association—a nonprofit organization based in the United States—showed that in May 2024, 43% of adults reported higher anxiety levels compared to the prior year, up from 37% in 2023 and 32% in 2022. As a result, the rising preference for personalized medicine is fueling growth in the anemia and blood disorder drugs market.
Anemia And Other Blood Disorder Drugs Market Segment Outlook: Which Categories Are Expanding The Fastest?
The anemia and other blood disorder drugs market covered in this report is segmented –
1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia
2) By Route of Administration: Oral, Injectable
3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
Subsegments:
1) By Iron Deficiency Anemia: Oral Iron Supplements, Injectable Iron Supplements, Iron Fortified Foods
2) By Chronic Kidney Disease Anemia: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion
3) By Sickle Cell Anemia: Hydroxyurea, Blood Transfusions, Gene Therapy, Pain Management Drugs
4) By Aplastic Anemia: Immunosuppressive Therapy, Stem Cell Transplantation, Erythropoiesis-Stimulating Agents (ESAs)
Anemia And Other Blood Disorder Drugs Market Trends Influencing Long-Term Demand
Major pharmaceutical players in the anemia and related blood disorder drugs market are intensively concentrating on developing innovative treatments to enhance patient outcomes, diversify available therapeutic choices, and bolster their market standing. These novel pharmaceuticals represent cutting-edge therapies that introduce fresh mechanisms of action, deliver stronger effectiveness, or feature more favorable safety profiles when weighed against standard care, thereby addressing unfulfilled medical requirements in disorders like anemia and myelodysplastic syndromes. A notable example occurred in August 2023, when Bristol-Myers Squibb Company, headquartered in the United States, secured FDA approval for Reblozyl as the initial therapy for anemia in adults with lower-risk myelodysplastic syndromes. This achievement marked the first drug to prove its superiority over an erythropoiesis-stimulating agent in this clinical context, with findings from the Phase 3 COMMANDS trial revealing that nearly double the proportion of patients on Reblozyl reached at least 12 weeks free from blood transfusions while also showing concurrent hemoglobin improvements compared to those administered Epoetin alfa.
Anemia And Other Blood Disorder Drugs Market Key Companies And Competitive Benchmarking
Major companies operating in the anemia and other blood disorder drugs market are Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Grifols S.A.
Access The Complete Anemia And Other Blood Disorder Drugs Market Report:
Anemia And Other Blood Disorder Drugs Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the anemia and other blood disorder drugs market in 2025. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
